PT - JOURNAL ARTICLE AU - Carmelo Carmona-Rivera AU - Yu Zhang AU - Kerry Dobbs AU - Tovah E. Markowitz AU - Clifton L. Dalgard AU - Andrew J. Oler AU - Dillon R. Claybaugh AU - Deborah Draper AU - Meng Truong AU - Ottavia M. Delmonte AU - Francesco Licciardi AU - Ugo Ramenghi AU - Nicoletta Crescenzio AU - Luisa Imberti AU - Alessandra Sottini AU - Virginia Quaresima AU - Chiara Fiorini AU - Valentina Discepolo AU - Andrea Lo Vecchio AU - Alfredo Guarino AU - Luca Pierri AU - Andrea Catzola AU - Andrea Biondi AU - Paolo Bonfanti AU - Maria Cecilia Poli Harlowe AU - Yasmin Espinosa AU - Camila Astudillo AU - Emma Rey-Jurado AU - Cecilia Vial AU - Javiera de la Cruz AU - Ricardo Gonzalez AU - Cecilia Pinera AU - Jacqueline W. Mays AU - Ashley Ng AU - Andrew Platt AU - NIH COVID Autopsy Consortium AU - COVID STORM Clinicians AU - Beth Drolet AU - John Moon AU - Edward W. Cowen AU - Heather Kenney AU - Sarah E. Weber AU - Riccardo Castagnoli AU - Mary Magliocco AU - Michael A. Stack AU - Gina Montealegre AU - Karyl Barron AU - Stephen M. Hewitt AU - Lisa M. Arkin AU - Daniel S. Chertow AU - Helen C. Su AU - Luigi D. Notarangelo AU - Mariana J. Kaplan TI - Multicenter analysis of neutrophil extracellular trap dysregulation in adult and pediatric COVID-19 AID - 10.1101/2022.02.24.22271475 DP - 2022 Jan 01 TA - medRxiv PG - 2022.02.24.22271475 4099 - http://medrxiv.org/content/early/2022/03/03/2022.02.24.22271475.short 4100 - http://medrxiv.org/content/early/2022/03/03/2022.02.24.22271475.full AB - Dysregulation in neutrophil extracellular trap (NET) formation and degradation may play a role in the pathogenesis and severity of COVID-19; however, its role in the pediatric manifestations of this disease including MIS-C and chilblain-like lesions (CLL), otherwise known as “COVID toes”, remains unclear. Studying multinational cohorts, we found that, in CLL, NETs were significantly increased in serum and skin. There was geographic variability in the prevalence of increased NETs in MIS-C, in association with disease severity. MIS-C and CLL serum samples displayed decreased NET degradation ability, in association with C1q and G-actin or anti-NET antibodies, respectively, but not with genetic variants of DNases. In adult COVID-19, persistent elevations in NETs post-disease diagnosis were detected but did not occur in asymptomatic infection. COVID-19-affected adults displayed significant prevalence of impaired NET degradation, in association with anti-DNase1L3, G-actin, and specific disease manifestations, but not with genetic variants of DNases. NETs were detected in many organs of adult patients who died from COVID-19 complications. Infection with the Omicron variant was associated with decreased levels of NETs when compared to other SARS-CoV-2 strains. These data support a role for NETs in the pathogenesis and severity of COVID-19 in pediatric and adult patients.Summary NET formation and degradation are dysregulated in pediatric and symptomatic adult patients with various complications of COVID-19, in association with disease severity. NET degradation impairments are multifactorial and associated with natural inhibitors of DNase 1, G-actin and anti-DNase1L3 and anti-NET antibodies. Infection with the Omicron variant is associated with decreased levels of NETs when compared to other SARS-CoV-2 strains.Competing Interest StatementThe authors have declared no competing interest.Funding StatementSupported by the Intramural Research Program at NIAMS/ (ZIAAR041199 to MJK), NIAID (ZIA AI001270-01 to LDN and ZIAAI001265 to HCS), NIDCR (ZIADE000747 to JM),the Wisconsin Partnership Program 2020 Strategic COVID-19 Grant (to LA), FONDECYT 11181222 (to MCP), ANID 0999 (to MCV and MCP), and Regione Lombardia.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All individuals were enrolled in protocols approved by local Institutional Review Boards (IRBs: Comite Etico Cientifico Facultad de Medicina Clinica Alemana Universidad del Desarrollo, Santiago, Chile (protocol 2020-41); Comitato Etico Interaziendale A.O.U. Citta della Salute e della Scienza di Torino, Turin, Italy (protocol 00282/2020); Ethics Committee of the University of Naples Federico II, Naples, Italy (protocol 158/20); Comitato Etico Provinciale of Brescia, Italy (protocol NP4000); University of Milano Bicocca, San Gerardo Hospital, Monza; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA (protocols NCT04582903, NCT03394053 and NCT03610802); University of Wisconsin Madison (protocol 2020-0667).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study work are contained in the manuscript